Skip to main content
1 minArticle

Lifileucel promising against unresponsive malignant melanoma

By June 2, 2021No Comments

Lifileucel shows promise in metastatic-melanoma patients whose disease had progressed on standard immune-checkpoint inhibitors (ICI) and other therapies, according to a small open-label trial. “Lifileucel is a ground-breaking form of cellular immunotherapy that utilizes the immune cells of patients derived from their own tumors as a treatment,

Source: Reuters Health

Leave a Reply

error: